Results 141 to 150 of about 98,010,213 (261)

SARS-CoV-2 Neutralizing Antibodies 2.0

open access: yesViruses
As the SARS-CoV-2 mutates, especially into those variants causing immune escape, COVID-19 continues to wreak havoc [...]
openaire   +3 more sources

Beyond Nature's Blueprint: Macrocyclic Peptides Containing Unnatural Amino Acids in Therapeutic Development

open access: yesAngewandte Chemie, EarlyView.
Strategic incorporation of unnatural amino acids transforms macrocyclic peptides into drug‐like molecules capable of engaging challenging targets. These building blocks enhance stability, permeability, and bioavailability, accelerating the development of next‐generation peptide therapeutics.
Krishna K. Sharma   +5 more
wiley   +1 more source

Recent Advances in Virus–Host Interactions, Antiviral Bioactive Compounds, and Breeding for Disease Resistance of Porcine Epidemic Diarrhea Virus

open access: yesAnimal Research and One Health, EarlyView.
Basic research on the PEDV infection cycle and virus–host interactions advances the development of anti‐PEDV drugs and disease‐resistant breeding and helps strengthen disease prevention and control while reducing economic losses in the swine industry.
Heyong Wu   +8 more
wiley   +1 more source

Differences in SARS‐CoV‐2 Antigen Persistence in Individuals With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A RECOVER‐Adult Cohort Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective Individuals with systemic autoimmune rheumatic diseases (SARDs) are at risk for worse acute and post–acute COVID‐19 outcomes, though whether individuals with SARDs have longer persistence of viral antigens after COVID‐19 has not been studied.
Naomi J. Patel   +18 more
wiley   +1 more source

Updated COVID‐19 Vaccines and Health Outcomes in Patients With Autoimmune Rheumatic Conditions

open access: yesArthritis &Rheumatology, EarlyView.
Objective We aimed to assess the association between COVID‐19 vaccination status and COVID‐19‐related hospital admissions, need for mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and death in people with autoimmune rheumatic conditions. Methods We conducted a retrospective cohort study using National Clinical Cohort Collaborative
Lesley E. Jackson   +127 more
wiley   +1 more source

Higher risk of Long COVID among patients with autoimmune rheumatic diseases and immunomodulatory therapy: a retrospective cohort analysis of national US data.

open access: yesArthritis &Rheumatology, Accepted Article.
Background Little is known about the prevalence of and factors associated with Long COVID in patients with autoimmune rheumatic diseases (AIRDs). Methods We conducted a retrospective cohort study using data from the National Clinical Cohort Collaborative (N3C).
Namrata Singh   +11 more
wiley   +1 more source

Delineating the functional activity of antibodies with cross-reactivity to SARS-CoV-2, SARS-CoV-1 and related sarbecoviruses.

open access: yesPLoS Pathogens
The recurring spillover of pathogenic coronaviruses and demonstrated capacity of sarbecoviruses, such SARS-CoV-2, to rapidly evolve in humans underscores the need to better understand immune responses to this virus family.
Felicitas Ruiz   +14 more
doaj   +1 more source

Dose‐related propofol resistance in COVID‐19 patients: Altered drug plasma levels, mechanistic insights from neuronal‐derived extracellular vesicles and miRNA analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Critical care for COVID‐19 patients presents unique challenges, particularly in sedation management. Patients demonstrate notable dose‐related resistance to propofol, potentially due to complex pharmacokinetic alterations. Emerging evidence suggests that plasma extracellular vesicle‐associated miRNA represents valuable predictive ...
Debora Curci   +10 more
wiley   +1 more source

Ferritin as a Nanoparticle Scaffold for Plant‐Produced Next‐Generation Subunit Vaccines

open access: yesBiotechnology and Bioengineering, EarlyView.
ABSTRACT Protein nanoparticles offer an innovative approach to next‐generation subunit vaccine development by displaying antigenic sequences on the nanoparticle surface. Compared to traditional subunit vaccines, protein nanoparticle vaccines often show improved interaction with the immune system due to their particulate size and repetitive epitope ...
Jordan T. VanderBurgt   +3 more
wiley   +1 more source

Characterization of Immune Responses to RBD‐SD1 Nanoparticle Vaccines Derived From ACE2‐Capable HKU5‐CoV‐2, NeoCoV, and HKU5 Merbecoviruses

open access: yesBiotechnology and Bioengineering, EarlyView.
SpyCatcher‐mi3 nanoparticles presenting HKU5, NeoCoV, and HKU5‐CoV‐2 RBD‐SD1 induced strong, cross‐reactive IgG responses in immunized mice. The surrogate virus neutralization test demonstrated strong activity in sera from homologous vaccination. ABSTRACT Recent discoveries of merbecoviruses such as HKU5, NeoCoV, and HKU5‐CoV‐2 that use angiotensin ...
Peter J. Halfmann   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy